$OSCR · Oscar Health, Inc.
Oscar Health filed an 8-K under Item 7.01 (Regulation FD Disclosure) on September 16, 2026, in connection with its 2026 Investor Day. The company raised its full-year 2026 Earnings from Operations guidance to $600M–$800M, a $100M increase from the prior $500M–$700M range. It also improved its Medical Loss Ratio target by 50 basis points to 81.0%–82.0%, while reaffirming Total Revenue guidance of $18.7B–$19.0B and SG&A Expense Ratio of 15.6%–16.1%.
- FY2026 Earnings from Operations guidance raised to $600M–$800M, a $100M increase at both ends from prior $500M–$700M.
- Medical Loss Ratio target improved 50 bps to 81.0%–82.0%, signaling better claims cost management.
- FY2026 Total Revenue guidance reaffirmed at $18.7B–$19.0B.
- SG&A Expense Ratio guidance reaffirmed at 15.6%–16.1%.
- Guidance update released ahead of 2026 Investor Day presentation on September 16, 2026.
Extended-hours trading shows OSCR at $33.00, up +1.73% vs the regular-session close of $32.44, indicating a positive initial reaction to the raised profit guidance. Regular-session trading had closed before the filing; the after-hours move suggests the market is rewarding the $100M operating income uplift.
A $100M operating income guidance raise with improved loss-ratio expectations signals strengthening underwriting discipline at an $8.4B-market-cap insurer approaching sustained profitability.
The MLR improvement to 81.0%–82.0% keeps Oscar comfortably within the ACA medical loss ratio rebate threshold of 80%, a key metric for individual-market insurers.
Forward-looking statements are subject to risks detailed in the 2025 10-K; actual results may differ materially from the raised guidance due to claims cost volatility and other factors beyond Oscar's control.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.